The traditional 3+3 dose escalation design has dominated Phase I oncology trials for over two decades (Le Tourneau et al., 2009, Kurzrock, 2021). Three patients per cohort, fixed escalation increments,…
Read More
Navigating AI in Professional Services: Adnovate’s Confidentiality-First Approach Artificial intelligence offers the potential for tremendous productivity gains for consulting firms, but must be used cautiously and responsibly. At Adnovate, we…
Read More
